Washington, D.C. partner, and co-chair of the Intellectual Property Group, Bob Stoll spoke on a panel at the 2017 BIO International Convention on June 20 and was quoted in a subsequent Life Sciences Intellectual Property Review article titled, “BIO 2017: Industry at a Crossroads Over Section 101.”

Bob was joined by other IP authorities in discussing the future of patent subject matter eligibility in relation to the biotechnology industry. During the panel, he outlined three legislative proposals for amending patent subject matter eligibility by the IP law section of the American Bar Association, the American Intellectual Property Law Association, and the Intellectual Property Owners Association. Bob believes these proposals are a significant move in changing the current interpretation of patent legislation.

Source: Life Sciences Intellectual Property Review